19:30 , Dec 21, 2018 |  BC Week In Review  |  Company News

Furen gets rights to AZD0364 from AstraZeneca

Shanghai Furen Medicine R&D Co. Ltd. (Shanghai, China) gained Chinese rights to cancer candidate AZD0364 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Shanghai Furen is a subsidiary of Furen Medicines Group Co. Ltd. (Zhengzhou, China). AZD0364 is...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro , cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme...
22:18 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

BioMed Valley's ulixertinib leads to partial responses in Phase I for solid tumors

BioMed Valley Discoveries Inc. (Kansas City, Mo.) said twice-daily oral ulixertinib (BVD-523) at doses of ≥600 mg led to 14 partial responses in about 101 evaluable patients with advanced solid tumors in a two-part Phase...
01:18 , Dec 13, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived liver and bile duct cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by treating patient tumor samples with collagenase and deoxyribonuclease I (DNASE1)...
22:33 , Nov 21, 2017 |  BC Extra  |  Preclinical News

New tool for degradation of endogenous proteins

In a study published in Cell , researchers at Medical Research Council Laboratory of Molecular Biology (MRC LMB) and colleagues describe a new protein degradation technique called Trim-Away that harnesses a naturally occurring ubiquitinating protein...
02:08 , Jul 26, 2017 |  BC Extra  |  Company News

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to...
21:51 , Apr 19, 2017 |  BC Week In Review  |  Clinical News

KO-947: Ph I started

Kura began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV KO-947 in about 72 patients. Kura Oncology Inc. (NASDAQ:KURA), La Jolla, Calif.  Product: KO-947   Business: Cancer  Molecular target: MAP kinase 1 (...
21:51 , Apr 19, 2017 |  BC Week In Review  |  Clinical News

KO-947: Ph I started

Kura began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV KO-947 in about 72 patients. Kura Oncology Inc. (NASDAQ:KURA), La Jolla, Calif.  Product: KO-947   Business: Cancer  Molecular target: MAP kinase 1 (...
14:13 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Skin cancer Mouse studies suggest dual inhibition of MAP2K1 / MAP2K2 or MAPK1 / MAPK3 could help treat PTEN hamartoma tumor syndrome (PHTS), a type of skin hyperplasia that can become malignant. In a...
07:00 , Aug 11, 2016 |  BC Innovations  |  Product R&D

SHP-2 sets sail

Novartis AG researchers have revived a once-promising cancer target - a protein tyrosine phosphatase - by departing from the rote strategy of blocking its active site, and arresting the molecule in its inactive form instead....